409 related articles for article (PubMed ID: 26706121)
1. Targeting the androgen receptor in metastatic castrate-resistant prostate cancer: A review.
Anantharaman A; Friedlander TW
Urol Oncol; 2016 Aug; 34(8):356-67. PubMed ID: 26706121
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor splicing variant 7: Beyond being a constitutively active variant.
Shao C; Yu B; Liu Y
Life Sci; 2019 Oct; 234():116768. PubMed ID: 31445027
[TBL] [Abstract][Full Text] [Related]
3. Strategies for targeting the androgen receptor axis in prostate cancer.
Carver BS
Drug Discov Today; 2014 Sep; 19(9):1493-7. PubMed ID: 25107669
[TBL] [Abstract][Full Text] [Related]
4. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C
Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
Crona DJ; Milowsky MI; Whang YE
Clin Pharmacol Ther; 2015 Dec; 98(6):582-9. PubMed ID: 26331358
[TBL] [Abstract][Full Text] [Related]
6. Resistance to Hormonal Therapy in Prostate Cancer.
Berruti A; Dalla Volta A
Handb Exp Pharmacol; 2018; 249():181-194. PubMed ID: 28353036
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
8. Interference with the androgen receptor protein stability in therapy-resistant prostate cancer.
Lakshmana G; Baniahmad A
Int J Cancer; 2019 Apr; 144(8):1775-1779. PubMed ID: 30125354
[TBL] [Abstract][Full Text] [Related]
9. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
Chung C; Abboud K
Am J Health Syst Pharm; 2022 Jul; 79(15):1224-1235. PubMed ID: 35390118
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer.
Gupta S; Vanderbilt C; Abida W; Fine SW; Tickoo SK; Al-Ahmadie HA; Chen YB; Sirintrapun SJ; Chadalavada K; Nanjangud GJ; Bialik A; Morris MJ; Scher HI; Ladanyi M; Reuter VE; Gopalan A
Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):507-516. PubMed ID: 32094488
[TBL] [Abstract][Full Text] [Related]
11. [New generation of androgen receptor antagonist in castration resistant prostate cancer].
Uemura H
Nihon Rinsho; 2014 Dec; 72(12):2164-9. PubMed ID: 25518352
[TBL] [Abstract][Full Text] [Related]
12. [Inhibitors of the androgen receptor N‑terminal domain : Therapies targeting the Achilles' heel of various androgen receptor molecules in advanced prostate cancer].
Hupe MC; Offermann A; Perabo F; Chandhasin C; Perner S; Merseburger AS; Cronauer MV
Urologe A; 2018 Feb; 57(2):148-154. PubMed ID: 29147733
[TBL] [Abstract][Full Text] [Related]
13. Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer.
Sharp A; Welti J; Blagg J; de Bono JS
Clin Cancer Res; 2016 Sep; 22(17):4280-2. PubMed ID: 27330057
[TBL] [Abstract][Full Text] [Related]
14. Molecular model for neuroendocrine prostate cancer progression.
Chen R; Dong X; Gleave M
BJU Int; 2018 Oct; 122(4):560-570. PubMed ID: 29569310
[TBL] [Abstract][Full Text] [Related]
15. Targeting the androgen receptor and overcoming resistance in prostate cancer.
Einstein DJ; Arai S; Balk SP
Curr Opin Oncol; 2019 May; 31(3):175-182. PubMed ID: 30893145
[TBL] [Abstract][Full Text] [Related]
16. Investigational therapies targeting the androgen signaling axis and the androgen receptor and in prostate cancer - recent developments and future directions.
Isaacsson Velho P; Carducci MA
Expert Opin Investig Drugs; 2018 Oct; 27(10):811-822. PubMed ID: 30118330
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.
Wadosky KM; Koochekpour S
Oncotarget; 2016 Sep; 7(39):64447-64470. PubMed ID: 27487144
[TBL] [Abstract][Full Text] [Related]
18. [Androgen receptor-mediated processes in castrate-resistant metastatic prostate cancer].
Küronya Z; Bíró K; Gyergyay F; Géczi L
Orv Hetil; 2017 Jan; 158(2):42-49. PubMed ID: 28088885
[TBL] [Abstract][Full Text] [Related]
19. Catalytic inhibitors of DNA topoisomerase II suppress the androgen receptor signaling and prostate cancer progression.
Li H; Xie N; Gleave ME; Dong X
Oncotarget; 2015 Aug; 6(24):20474-84. PubMed ID: 26009876
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in allosteric androgen receptor inhibitors for the potential treatment of castration-resistant prostate cancer.
Martinez-Ariza G; Hulme C
Pharm Pat Anal; 2015; 4(5):387-402. PubMed ID: 26389532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
